What's New in the Treatment of Metastatic Breast Cancer: ESMO 2002
At the 27th Congress of the European Society of Medical Oncology (ESMO), several presentations highlighted different strategies in refinement of chemotherapeutic and hormonal interventions in the management of metastatic breast cancer (MBC) patients.

Ongoing Challenges in the Treatment of Gastric Cancer: ESMO 2002
Several abstracts regarding the management of advanced gastric cancer were presented at the 27th congress of the European Society for Medical Oncology (ESMO). The main focus for gastric cancer at ESMO was on improving the first-line treatment for metastatic or advanced disease.

New Approaches in the Treatment of Head and Neck Cancer: ESMO 2002
Five percent of all invasive cancers occur in the head and neck region with squamous cell being the predominant pathology. Less than 50% of individuals diagnosed with squamous cell carcinoma of the head and neck (SCCHN) will be cured.

Emerging Trends in the Treatment of Hormone Refractory Prostate Cancer
Prostate cancer is the second leading cause of cancer related death in men. Once hormone refractory disease develops, it is incurable. There have been several classes of cytotoxic agents identified with some activity against prostate cancer.

Advanced Non-Small Cell Lung Cancer- Where Are We Going?
Although the five-year survival rate is poor in early stage non-small cell lung cancer (NSCLC) treated with surgery alone, neither neoadjuvant or adjuvant chemotherapy can be recommended as standard. In patients with unresectable stage III disease, randomized trials have demonstrated the superiority of concurrent chemoradiation over sequential administration.